25 Oct 2019 by admin in UncategorizedComments New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic
17 Oct 2019 by admin in UncategorizedComments Syros Announces Update on Selective CDK7 Inhibitor Portfolio
07 Oct 2019 by admin in UncategorizedComments Tempest Therapeutics Names Biopharmaceutical Executive Stephen Brady as President and Chief Operating Office
03 Oct 2019 by admin in UncategorizedComments Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform
02 Oct 2019 by admin in UncategorizedComments NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer
24 Sep 2019 by admin in UncategorizedComments Crescendo Biologics Reaches Fifth Milestone in its Strategic Collaboration with Takeda
12 Sep 2019 by admin in UncategorizedComments Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
05 Sep 2019 by admin in UncategorizedComments Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer
04 Sep 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975, CNTX-6970 and CNTX-6016 Data Presentations at PAINWeek 2019 National Conference
01 Aug 2019 by admin in UncategorizedComments Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
25 Jul 2019 by admin in UncategorizedComments Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
23 Jul 2019 by admin in UncategorizedComments resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
23 Jul 2019 by admin in UncategorizedComments Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda
05 Jun 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
31 May 2019 by admin in UncategorizedComments Crescendo Biologics Announces Prestigious Academic Research Collaborations
28 May 2019 by admin in UncategorizedComments Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
24 May 2019 by admin in UncategorizedComments Crescendo Biologics Achieves Another Milestone in its Strategic Collaboration with Takeda
19 May 2019 by admin in UncategorizedComments Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals
16 May 2019 by admin in UncategorizedComments TEMPEST THERAPEUTICS STARTS PHASE I/IB CLINICAL TRIAL WITH FIRST-IN-CLASS PPAR ALPHA ANTAGONIST
15 May 2019 by admin in UncategorizedComments resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
08 May 2019 by admin in UncategorizedComments NextCure Announces Pricing of Initial Public Offering of Common Stock
01 May 2019 by admin in UncategorizedComments Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
02 Apr 2019 by admin in UncategorizedComments Theodora Harold to be appointed new CEO at Crescendo Biologics
15 Mar 2019 by admin in UncategorizedComments Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019
07 Mar 2019 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs
04 Mar 2019 by admin in UncategorizedComments NextCure and Yale Publish Nature Medicine Paper Detailing Novel Immunomedicine Target Siglec-15
28 Feb 2019 by admin in UncategorizedComments Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019
12 Feb 2019 by admin in UncategorizedComments NextCure Announces Formation of Scientific Advisory Board to Guide Development of its Portfolio of Immunomedicines
06 Jan 2019 by admin in UncategorizedComments Syros Announces Strategic Priorities and Expected Milestones
03 Jan 2019 by admin in UncategorizedComments Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda
05 Dec 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
13 Nov 2018 by admin in UncategorizedComments Tempest Data Provide POC for PPAR Alpha’s Role in Cancer
06 Nov 2018 by admin in UncategorizedComments resTORbio Appoints Michael Grissinger to its Board of Directors
06 Nov 2018 by admin in UncategorizedComments Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018
05 Nov 2018 by admin in UncategorizedComments Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®
16 Oct 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting
